Selective, Hsp90 competitive inhibitor (Ki
= 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+
ATPase. Induces degradation of HER-2 in vitro
= 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren et al.
Mol.Cancer Ther., 2009;8:921
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin et al.